Loading company…
Xynomic Pharmaceuticals develops cancer treatments, led by its candidate Abexinostat, which is being studied in lymphoma and kidney cancer.
Headquartered in Shanghai, China, Xynomic Pharmaceuticals develops and commercializes cancer treatments, with its lead drug candidate Abexinostat under study in follicular lymphoma and kidney cancer. The company was founded by Yinglin Xu and operates in China and the United States. Its Series B financing in June 2018 included Hakim Unique Internet Co., Ltd. and Northern Light Venture Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in